share_log

Shanghai Universal BiotechLtd's (SZSE:301166) Sluggish Earnings Might Be Just The Beginning Of Its Problems

上海ユニバーサルバイオテック株式会社(SZSE:301166)の不振な収益は、その問題の始まりに過ぎないかもしれません。

Simply Wall St ·  05/03 18:29

The market rallied behind Shanghai Universal Biotech Co.,Ltd.'s (SZSE:301166) stock, leading do a rise in the share price after its recent weak earnings report. Sometimes, shareholders are willing to ignore soft numbers with the hope that they will improve, but our analysis suggests this is unlikely for Shanghai Universal BiotechLtd.

earnings-and-revenue-history
SZSE:301166 Earnings and Revenue History May 3rd 2024

The Impact Of Unusual Items On Profit

Importantly, our data indicates that Shanghai Universal BiotechLtd's profit received a boost of CN¥4.5m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. We can see that Shanghai Universal BiotechLtd's positive unusual items were quite significant relative to its profit in the year to March 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Shanghai Universal BiotechLtd.

Our Take On Shanghai Universal BiotechLtd's Profit Performance

As previously mentioned, Shanghai Universal BiotechLtd's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that Shanghai Universal BiotechLtd's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. In further bad news, its earnings per share decreased in the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. When we did our research, we found 4 warning signs for Shanghai Universal BiotechLtd (2 are concerning!) that we believe deserve your full attention.

This note has only looked at a single factor that sheds light on the nature of Shanghai Universal BiotechLtd's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする